Patents by Inventor Eric D. Turtle

Eric D. Turtle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES
    Publication number: 20230250091
    Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface asialoglycoprotein receptor (ASGPR). The cell surface ASGPR binding compounds can trigger the receptor to internalize into the cell a bound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided herein methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.
    Type: Application
    Filed: April 14, 2023
    Publication date: August 10, 2023
    Inventors: Brett Bradley BUSCH, Justin Thomas ERNST, Garrick K. PACKARD, Jason G. LEWIS, Eric D. TURTLE
  • Cell Surface Receptor Binding Compounds and Conjugates
    Publication number: 20230158155
    Abstract: The present disclosure provides a class of compounds including a ligand moiety that specifically binds to a cell surface receptor, such as a mannose-6-phosphate receptor (M6PR) or a cell surface asialoglycoprotein receptor (ASGPR). The cell surface M6PR or ASGPR binding compounds can trigger the receptor to internalize into the cell abound compound. The ligand moieties of this disclosure can be linked to a variety of moieties of interest without impacting the specific binding to, and function of, the cell surface receptor, e.g., M6PR or ASGPR. Also provided are compounds that are conjugates of the ligand moieties linked to a biomolecule, such as an antibody, which conjugates can harness cellular pathways to remove specific proteins of interest from the cell surface or from the extracellular milieu. Also provided are methods of using the conjugates to target a polypeptide of interest for sequestration and/or lysosomal degradation.
    Type: Application
    Filed: January 8, 2021
    Publication date: May 25, 2023
    Inventors: Brett Bradley BUSCH, Justin Thomas ERNST, Garrick K. PACKARD, Jason G. LEWIS, Eric D. TURTLE
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 11229637
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 25, 2022
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20210060000
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-assocaited conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: March 13, 2020
    Publication date: March 4, 2021
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10646482
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 22, 2018
    Date of Patent: May 12, 2020
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190240213
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: August 22, 2018
    Publication date: August 8, 2019
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 10092558
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 9, 2018
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20170035747
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: April 19, 2016
    Publication date: February 9, 2017
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 9339527
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: May 17, 2016
    Assignee: FibroGen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20160009653
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoictin-associated conditions.
    Type: Application
    Filed: September 21, 2015
    Publication date: January 14, 2016
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Cyanoisoquinoline compounds and methods of use thereof
    Patent number: 9174976
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 3, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Thiochromene derivatives as HIF hydroxylase inhibitors
    Patent number: 9149476
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: October 6, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Wen-Bin Ho, Lee A. Flippin, Craig Mossman, Eric D. Turtle, Lee R. Wright
  • THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS
    Publication number: 20150182528
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: December 24, 2014
    Publication date: July 2, 2015
    Inventors: Wen-Bin Ho, Lee A. Flippin, Craig Mossman, Eric D. Turtle, Lee R. Wright
  • Thienopyridine compounds, and methods of use thereof
    Patent number: 9000006
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: April 7, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20150031696
    Abstract: The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions.
    Type: Application
    Filed: May 28, 2014
    Publication date: January 29, 2015
    Applicant: FIBROGEN, INC.
    Inventors: Michael Arend, Lee A. Flippin, Min Wu, Eric D. Turtle, Wen-Bin Ho, Shaojiang Deng
  • Thiochromene derivatives as HIF hydroxylase inhibitors
    Patent number: 8927591
    Abstract: The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: January 6, 2015
    Assignee: Fibrogen, Inc.
    Inventors: Wen-Bin Ho, Lee R. Wright, Eric D. Turtle, Craig Mossman, Lee A. Flippin
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8916585
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: December 23, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20140343094
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Application
    Filed: May 21, 2014
    Publication date: November 20, 2014
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du
  • NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF
    Publication number: 20140221422
    Abstract: The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).
    Type: Application
    Filed: April 9, 2014
    Publication date: August 7, 2014
    Applicant: FIBROGEN, INC.
    Inventors: Eric D. Turtle, Lee A. Flippin, Michael P. Arend, Heng Cheng
  • Nitrogen-containing heteroaryl compounds and methods of use thereof
    Patent number: 8765956
    Abstract: The present invention relates to compounds suitable for use in mediating hypoxia inducible factor and for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: July 1, 2014
    Assignee: Fibrogen, Inc.
    Inventors: Michael P. Arend, Lee A. Flippin, Volkmar Guenzler-Pukall, Wen-Bin Ho, Eric D. Turtle, Xiaohui Du